Traders Are Bullish BioCryst Pharmaceuticals, Inc. (BCRX) After The Stock Formed Bullish Descending Triangle Chart Pattern

December 8, 2017 - By Maria Brooks

Investors sentiment increased to 1.68 in Q2 2017. Its up 0.18, from 1.5 in 2017Q1. It is positive, as 15 investors sold BioCryst Pharmaceuticals, Inc. shares while 19 reduced holdings. 18 funds opened positions while 39 raised stakes. 66.24 million shares or 8.58% more from 61.01 million shares in 2017Q1 were reported.
California State Teachers Retirement owns 141,883 shares or 0% of their US portfolio. Citadel Advsr Ltd reported 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Voya Inv Mgmt Limited Com reported 0% stake. Advisory Svcs Ltd Company holds 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 6,500 shares. Ameritas Investment reported 6,697 shares. Pacad Investment has 0.03% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 35,200 shares. Baker Bros Advsr Limited Partnership holds 0.57% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 11.72 million shares. 468,882 were reported by Tiaa Cref Inv Mngmt Ltd Liability Com. Jpmorgan Chase & owns 244,613 shares. Ellington Management Gru Limited Liability Corp holds 0.03% or 34,600 shares. Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 1,801 shares. Nationwide Fund Advsrs reported 46,149 shares. Janney Montgomery Scott Limited Liability Corp accumulated 33,335 shares. 168,685 were reported by Acuta Ptnrs Lc. Glenmede Tru Na has 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 200 shares.

The stock of BioCryst Pharmaceuticals, Inc. (BCRX) formed a descending triangle with $4.75 target or 4.00 % above today’s $4.57 share price. The 7 months triangle pattern indicates low risk for the $449.71M company. If the $4.75 price target is reached, the company will be worth $17.99M more.
The descending triangle is in our view more reliable than the ascending one. The descending triangle pattern has break even failure rate for up and down breakouts of 7% and 16%, respectively. The average rise and decline is 47% and 16%. The throwback or so called pullback rates are: 37% and 54%. The stocks meeting their targets is high for this type of breakout: 84% and 54% percent.

The stock decreased 0.44% or $0.02 during the last trading session, reaching $4.57. About 663,349 shares traded. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has risen 75.08% since December 8, 2016 and is uptrending. It has outperformed by 58.38% the S&P500.

Analysts await BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to report earnings on February, 26. They expect $-0.15 EPS, down 150.00 % or $0.09 from last year’s $-0.06 per share. After $-0.18 actual EPS reported by BioCryst Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -16.67 % EPS growth.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Ratings Coverage

Among 13 analysts covering BioCryst Pharmaceuticals (NASDAQ:BCRX), 11 have Buy rating, 0 Sell and 2 Hold. Therefore 85% are positive. BioCryst Pharmaceuticals had 31 analyst reports since August 7, 2015 according to SRatingsIntel. The stock has “Buy” rating by Noble Financial on Friday, May 26. The rating was upgraded by J.P. Morgan to “Buy” on Wednesday, September 6. On Wednesday, September 6 the stock rating was upgraded by Jefferies to “Buy”. PiperJaffray upgraded BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Friday, August 12 to “Overweight” rating. The firm has “Market Outperform” rating by JMP Securities given on Friday, December 16. The rating was maintained by FBR Capital on Tuesday, February 9 with “Outperform”. The firm has “Hold” rating by Needham given on Tuesday, February 9. The rating was downgraded by JMP Securities on Thursday, August 4 to “Market Perform”. The stock has “Buy” rating by Noble Financial on Tuesday, August 8. The stock has “Overweight” rating by JP Morgan on Wednesday, September 6.

More news for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) were recently published by:, which released: “BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse Q3 2017 Results …” on November 07, 2017.‘s article titled: “Biotech Stock Performance Review — BioCryst Pharma, Celgene, Exelixis, and Geron” and published on November 21, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.